Stockreport

Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight

Verona Pharma plc - American Depositary Shares  (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
PDF According to DelveInsight's analysis, the chronic refractory cough market size is expected to increase due to an increase in disease prevalence, the growth in the market [Read more]